A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.

The invasive nature of liver biopsy makes the histopathological diagnosis of non-alcoholic fatty liver disease (NAFLD) difficult and its diagnostic performance unsatisfactory. The present study aimed to identify a serum microRNA (miRNA) expression profile that could serve as a novel diagnostic bioma...

Full description

Bibliographic Details
Main Authors: Youwen Tan, Guohong Ge, Tengli Pan, Danfeng Wen, Jianhe Gan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4139327?pdf=render
_version_ 1818540653282328576
author Youwen Tan
Guohong Ge
Tengli Pan
Danfeng Wen
Jianhe Gan
author_facet Youwen Tan
Guohong Ge
Tengli Pan
Danfeng Wen
Jianhe Gan
author_sort Youwen Tan
collection DOAJ
description The invasive nature of liver biopsy makes the histopathological diagnosis of non-alcoholic fatty liver disease (NAFLD) difficult and its diagnostic performance unsatisfactory. The present study aimed to identify a serum microRNA (miRNA) expression profile that could serve as a novel diagnostic biomarker for NAFLD.Serum miRNA expression was investigated using three cohorts comprising 465 participants (healthy controls and NAFLD patients) recruited between August 2010 and June 2013. miRNA expression was initially screened by Illumina sequencing using serum samples pooled from 20 patients and 20 controls. Quantitative reverse transcriptase polymerase chain reaction assay was then used to evaluate the expression of selected miRNAs. A logistic regression model was constructed using a training cohort (n = 242) and validated using another cohort (n = 183). The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy.We identified an miRNA panel (hsa-miR-122-5p, hsa-miR-1290, hsa-miR-27b-3p, and hsa-miR-192-5p) with a high diagnostic accuracy for NAFLD. The satisfactory diagnostic performance of the miRNA panel remained regardless of the NAFLD activity score (NAS) status. There was significant difference between the AUC values of the miRNA panel and those of ALT (AUC = 0.786, 95% CI = 0.717-0.855; P = 0.142) and FIB-4 (AUC = 0.795, 95% CI = 0.730-0.860; sensitivity = 69.9%, specificity = 83.7%.We identified a serum microRNA panel with considerable clinical value in NAFLD diagnosis. The results indicate that the miRNA panel is a more sensitive and specific biomarker for NAFLD than ALT and FIB-4.
first_indexed 2024-12-11T21:58:12Z
format Article
id doaj.art-4e50e8b9570f4af0930f228a8589691c
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T21:58:12Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-4e50e8b9570f4af0930f228a8589691c2022-12-22T00:49:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10519210.1371/journal.pone.0105192A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.Youwen TanGuohong GeTengli PanDanfeng WenJianhe GanThe invasive nature of liver biopsy makes the histopathological diagnosis of non-alcoholic fatty liver disease (NAFLD) difficult and its diagnostic performance unsatisfactory. The present study aimed to identify a serum microRNA (miRNA) expression profile that could serve as a novel diagnostic biomarker for NAFLD.Serum miRNA expression was investigated using three cohorts comprising 465 participants (healthy controls and NAFLD patients) recruited between August 2010 and June 2013. miRNA expression was initially screened by Illumina sequencing using serum samples pooled from 20 patients and 20 controls. Quantitative reverse transcriptase polymerase chain reaction assay was then used to evaluate the expression of selected miRNAs. A logistic regression model was constructed using a training cohort (n = 242) and validated using another cohort (n = 183). The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy.We identified an miRNA panel (hsa-miR-122-5p, hsa-miR-1290, hsa-miR-27b-3p, and hsa-miR-192-5p) with a high diagnostic accuracy for NAFLD. The satisfactory diagnostic performance of the miRNA panel remained regardless of the NAFLD activity score (NAS) status. There was significant difference between the AUC values of the miRNA panel and those of ALT (AUC = 0.786, 95% CI = 0.717-0.855; P = 0.142) and FIB-4 (AUC = 0.795, 95% CI = 0.730-0.860; sensitivity = 69.9%, specificity = 83.7%.We identified a serum microRNA panel with considerable clinical value in NAFLD diagnosis. The results indicate that the miRNA panel is a more sensitive and specific biomarker for NAFLD than ALT and FIB-4.http://europepmc.org/articles/PMC4139327?pdf=render
spellingShingle Youwen Tan
Guohong Ge
Tengli Pan
Danfeng Wen
Jianhe Gan
A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
PLoS ONE
title A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
title_full A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
title_fullStr A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
title_full_unstemmed A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
title_short A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
title_sort pilot study of serum micrornas panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease
url http://europepmc.org/articles/PMC4139327?pdf=render
work_keys_str_mv AT youwentan apilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT guohongge apilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT tenglipan apilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT danfengwen apilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT jianhegan apilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT youwentan pilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT guohongge pilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT tenglipan pilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT danfengwen pilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease
AT jianhegan pilotstudyofserummicrornaspanelaspotentialbiomarkersfordiagnosisofnonalcoholicfattyliverdisease